CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND IS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT 10.8
LICENSE AND SUPPLY AGREEMENT
INTRABIOTICS PHARMACEUTICALS, INC.
AND
BIOSEARCH ITALIA S.P.A.
MAY 8, 1998
LICENSE AND SUPPLY AGREEMENT
THIS LICENSE AND SUPPLY AGREEMENT (the "Agreement") is made effective
as of the 8th day of May, 1998 (the "Effective Date") by and between
INTRABIOTICS PHARMACEUTICALS, INC., a Delaware corporation having its principal
place of business at 0000 Xxxxx Xxxxx Xxxxxx, Xxxxxxxx Xxxx, Xxxxxxxxxx, XXX
00000 ("IntraBiotics") and BIOSEARCH ITALIA, S.P.A. an Italian corporation with
its principal place of business at xxx Xxxxxxx, 00, 00000 Xxxxxxxxx, Xxxxx
("BioSearch"). IntraBiotics and BioSearch are sometimes referred to herein
individually as a "Party" and collectively as the "Parties."
RECITALS
A. IntraBiotics is a biotechnology company interested in the
development of products useful for the treatment of infectious diseases or
conditions, and BioSearch is a pharmaceutical company interested in the
identification and development of naturally produced compounds useful for the
treatment of infectious disease, and the commercialization of products based
upon such compounds in Europe.
B. BioSearch discovered and is developing a proprietary compound,
Ramoplanin, that is believed to be useful for the treatment and prevention of
infectious diseases or conditions.
C. BioSearch is currently conducting clinical trials in Europe of [ * ]
formulation of Ramoplanin for the treatment or prevention of [*], and is also
developing a [*] formulation of Ramoplanin for the treatment of [*].
D. IntraBiotics desires to develop and commercialize formulations of
Ramoplanin other than [*] formulations for the treatment or prevention of
infectious diseases and conditions in the United States and Canada (including
the territories and possessions of each such country).
ARTICLE 1
DEFINITIONS
The following terms shall have the following meanings as used in this Agreement:
1.1 "AFFILIATE" means an entity that, directly or indirectly, through
one or more intermediaries, controls, is controlled by or is under common
control with BioSearch or IntraBiotics.
1.2 "BIOSEARCH KNOW-HOW" means Information which (i) BioSearch
discloses to IntraBiotics under this Agreement and (ii) is within the Control of
BioSearch. Notwithstanding anything herein to the contrary, BioSearch Know-how
shall exclude BioSearch Patents.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
1.
1.3 "BIOSEARCH PATENT" means a Patent which covers the discovery,
evaluation, manufacture, use, sale, offer for sale and/or importation of
Licensed Products within the Field, which Patent is owned or Controlled by
BioSearch, including without limitation BioSearch's interest in any Joint
Patents.
1.4 "BULK LICENSED COMPOUND" means the bulk form of the Licensed
Compound used to manufacture Licensed Products under this Agreement.
1.5 "COMMERCIALIZATION" shall mean all activities undertaken by
IntraBiotics relating to the manufacture and sale of Licensed Product in the
Territory, including advertising, education, marketing, distribution and
post-approval product support clinical studies conducted after Regulatory
Approval of a Licensed Product for a particular indication.
1.6 "CONTROL" means possession of the ability to grant a license or
sublicense as provided for herein without violating the terms of any agreement
or other arrangement with any Third Party.
1.7 "COST OF GOODS SOLD" means the aggregate of the cost to BioSearch
of [*] expenses reasonably incurred in connection with the above.
1.8 "DEVELOPMENT" means all activities relating to obtaining Regulatory
Approval of a Licensed Product, Licensed Product delivery systems and new
indications thereof and all activities relating to developing the ability to
manufacture the same.
1.9 "DRUG APPROVAL APPLICATION" means an application for Regulatory
Approval required before commercial sale or use of a Licensed Product as a drug
in a regulatory jurisdiction.
1.10 "EXCLUDED FORMULATIONS" means the formulations of the Licensed
Compound suitable solely for (i) [*] delivery of the Licensed Compound, (ii)
[*].
1.11 "FIELD" means the treatment or prevention of any human disease.
1.12 "IND" (OR "INVESTIGATIONAL NEW DRUG APPLICATION") means an
application as defined in the United States Food, Drug and Cosmetic Act and
applicable regulations promulgated thereunder to the United States Food and Drug
Administration (the "FDA"), or the equivalent application to the equivalent
agency in jurisdictions outside the United States, the filing of which is
necessary to commence clinical testing of Licensed Products in humans.
1.13 "INFORMATION" means (i) techniques and data within the Field,
including inventions, practices, methods, knowledge, know-how, skill,
experience, test data including pharmacological, toxicological and clinical test
data, analytical and quality control data or descriptions and (ii) compounds,
compositions of matter, assays and biological materials within the Field.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
2.
1.14 "INTRABIOTICS KNOW-HOW" means Information which (i) IntraBiotics
discloses to BioSearch under this Agreement and (ii) is within the Control of
IntraBiotics. Notwithstanding anything herein to the contrary, IntraBiotics
Know-how shall exclude IntraBiotics Patents.
1.15 "INTRABIOTICS PATENT" means a Patent which covers the manufacture,
use, sale, offer for sale and/or import of Licensed Products within the Field,
which Patent is owned or Controlled by IntraBiotics, including IntraBiotics'
interest in any Joint Patents.
1.16 "JOINT PATENT" shall have the meaning set forth in Section 10.3.
1.17 "KNOW-HOW" means BioSearch Know-how and/or IntraBiotics Know-how.
1.18 "LICENSED COMPOUND" means the compound known as Ramoplanin, which
was the subject of the Original IND.
1.19 "LICENSED PRODUCT" means any product including or incorporating
any formulation of the Licensed Compound other than an Excluded Formulation.
1.20 "NET SALES" means the amount invoiced for sales of a Licensed
Product in final dosage form by IntraBiotics, its Affiliates or its sublicensees
to a Third Party end user, less (i) discounts, including cash discounts, or
rebates (including government-mandated rebates), retroactive price reductions or
allowances actually allowed or granted from the billed amount, (ii) credits or
allowances actually granted upon claims, rejections or returns of such Licensed
Products, including recalls, (iii) freight, postage, shipping and insurance
charges paid for delivery of Licensed Product, to the extent billed, and (iv)
taxes, duties or other governmental charges levied on or measured by the billing
amount when included in billing, as adjusted for rebates and refunds.
In the event a Party is receiving royalties under this Agreement from
any Licensed Product sold in the form of a combination product containing one or
more active ingredients in addition to the Licensed Compound, Net Sales for such
combination product will be calculated by multiplying actual [*], as determined
by market prices of such portions if separately priced and sold, or if not so
priced and sold, as determined by mutual agreement of the parties. As used
herein, the term "active ingredient" does not include ingredients the primary
effect of which is the enhancement of drug delivery, even if such ingredients
have pharmacological activity.
1.21 "ORIGINAL IND" means IND number [*], which [*] filed for [*]
formulation of Ramoplanin with [*] and which was subsequently withdrawn on [*].
1.22 "OTHER LICENSEE" means any Third Party to which BioSearch has
granted a license under the BioSearch Patents and BioSearch Know-how for the
development or commercialization of Licensed Products or other products
containing the Licensed Compound.
1.23 "PATENT" means (i) valid and enforceable patents, re-examinations,
reissues, renewals, extensions, term restorations and foreign counterparts
thereof, and (ii) pending (at any
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
3.
time during the term of this Agreement) applications for United States patents
and foreign counterparts thereof.
1.24 "PHASE II CLINICAL TRIALS" means those trials on sufficient
numbers of patients that are designed to establish safety and assess the
biological activity of a drug for its intended use, and to define warnings,
precautions and adverse reactions that are associated with the drug in the to be
prescribed dosage range.
1.25 "PHASE III CLINICAL TRIALS" means those trials on sufficient
numbers of patients that are designed to establish that a drug is safe and
efficacious for its intended use, and to define warnings, precautions and
adverse reactions that are associated with the drug in the to be prescribed
dosage range, and supporting Regulatory Approval of such drug.
1.26 "PHASE III MILESTONE REPORT" means the report containing an
analysis of the Phase III Clinical Trial of a Licensed Product in the Territory
and an analysis of reported adverse experiences from such trial.
1.27 "REGULATORY APPROVAL" means any approvals (including pricing and
reimbursement approvals, if appropriate), product and/or establishment licenses,
registrations or authorizations of any federal, state or local regulatory
agency, department, bureau or other governmental entity, necessary for the
manufacture, use, storage, import, export or sale of Licensed Products in a
regulatory jurisdiction.
1.28 "SUPPLY PRICE" shall have the meaning set forth in Section 8.2.
1.29 "TERRITORY" means the United States and Canada and the territories
and possessions of each of the foregoing countries.
1.30 "THIRD PARTY" means any entity other than BioSearch or
IntraBiotics or their Affiliates.
1.31 "TRANSFER PRICE" shall have the meaning set forth in Section 7.9.
1.32 "VALID CLAIM" means a claim of (a) an issued patent, which claim
has not lapsed, been cancelled, or become abandoned and which claim has not been
declared invalid or unenforceable by a court of competent jurisdiction in a
decision from which no appeal has or can be taken, or (b) a patent application,
so long as such application is being prosecuted and the claim in question has
not been abandoned by the owner of the application (with the period of presumed
validity of a pending application not to exceed [*] years in countries).
ARTICLE 2
DEVELOPMENT
2.1 GENERAL. IntraBiotics shall be responsible for the Development of
Licensed Products in the Field and in the Territory, with support from BioSearch
as provided in this
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
4.
Agreement. Development of products including the Licensed Compound (including
without limitation Licensed Products) outside of the Territory, development of
products other than Licensed Products including the Licensed Compound in the
Field and in the Territory, and development of products including the Licensed
Compound (including without limitation Licensed Products) outside the Field and
in the Territory shall be conducted by BioSearch and/or the Other Licensees, if
any, outside the scope of this Agreement. However, in order to avoid the
duplication of cost and effort, and to optimize the results of worldwide
Development of Licensed Products, the Parties agree to exchange information
regarding their respective activities related to the Development of Licensed
Products as provided in this Agreement. In particular, the Parties intend to
exchange information regarding the clinical and non-clinical testing of products
including the Licensed Compound (including without limitation Licensed Products)
for indications in the Field.
2.2 DEVELOPMENT OF LICENSED PRODUCTS BY INTRABIOTICS.
(a) INTRABIOTICS COMMITMENT. IntraBiotics shall have the
right to utilize all relevant non-clinical and clinical data received from
BioSearch prior to the Effective Date and during the term of this Agreement
pursuant to Sections 2.3 and 2.4 for purposes of obtaining Regulatory
Approval of Licensed Products in the Field and in the Territory. IntraBiotics
hereby agrees to conduct, at its sole expense, all additional non-clinical
and clinical Development necessary to obtain Regulatory Approvals for
Licensed Products in the Field and in the Territory. IntraBiotics shall not
have any obligation to Develop Licensed Products for any particular
indication but may, at its option, develop Licensed Products for any
indication in the Field.
(b) DILIGENCE. IntraBiotics shall work diligently, consistent
with accepted business practices and legal requirements, to develop Licensed
Products in the Field and in the Territory.
(c) DELIVERY OF INFORMATION. IntraBiotics will provide to
BioSearch its Information regarding the Development of Licensed Products in the
Field, as set forth in Section 2.4, for use in development and commercialization
of products by BioSearch and, subject to Section 2.6, any Other Licensees
outside of the Territory. BioSearch and, subject to Section 2.6, any Other
Licensees shall be permitted to use and reference all such Information regarding
Development of Licensed Products in (i) any Drug Approval Application filed
outside the Territory and (ii) any Drug Approval Application filed within the
Territory with respect to either Licensed Products outside the Field, or
products other than Licensed Products that contain the Licensed Compound within
the Field. Notwithstanding the foregoing, BioSearch agrees that it shall treat
all Information provided by IntraBiotics pursuant to this Section 2.2(c) as
Confidential Information subject to the terms of Article 9.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
5.
(d) REGULATORY MATTERS.
(i) COMPLIANCE WITH REGULATIONS. IntraBiotics shall
conduct its efforts hereunder in compliance with all applicable regulatory
requirements.
(ii) DRUG APPROVAL APPLICATIONS. IntraBiotics
shall be responsible for preparing and filing Drug Approval Applications and
seeking Regulatory Approvals for Licensed Products in the Field and in the
Territory, including preparing all reports necessary for filing a Drug
Approval Application for Licensed Products in the Territory. IntraBiotics
shall be responsible for prosecuting all such Drug Approval Applications, and
BioSearch and, subject to Section 2.6, any Other Licensees shall have the
right of cross reference with respect thereto. In connection with all Drug
Approval Applications being prosecuted by IntraBiotics hereunder,
IntraBiotics agrees to provide BioSearch with a copy of all filings to
regulatory agencies that it makes hereunder. IntraBiotics shall provide to
BioSearch reports regarding the status of each pending and proposed Drug
Approval Application in the Territory within thirty (30) days after each June
30th and December 31st during the term of this Agreement. In the event that
any regulatory agency threatens or initiates any action to remove a Licensed
Product from the market in the Territory, IntraBiotics shall promptly notify
BioSearch of such communication.
2.3 DEVELOPMENT OBLIGATIONS OF BIOSEARCH.
(a) ACCESS TO BIOSEARCH AND OTHER LICENSEE INFORMATION.
(i) BioSearch has, prior to the Effective Date,
provided IntraBiotics a copy of the Original IND. BioSearch will comply with all
steps necessary to allow IntraBiotics to use the information contained in the
Original IND to file another IND for Licensed Products, including, if necessary,
[*] to the Original IND to IntraBiotics, provided that in the event [*] any
necessary rights of reference or access to the Original IND in connection with
BioSearch's development of the Excluded Formulations within the Territory.
(ii) BioSearch will, as soon as possible after the
Effective Date, provide IntraBiotics copies of all regulatory filings and the
results of all clinical and non-clinical testing of Licensed Products under the
control of or performed by BioSearch or any Other Licensees prior to the
Effective Date, to the extent that BioSearch is not restricted from providing
any such information that is owned or Controlled by such Other Licensees and to
the extent that such filings or information has not already been provided to
IntraBiotics.
(iii) During the term of this Agreement, BioSearch
will provide to IntraBiotics all Information in its possession regarding
Licensed Products in the Field (including Information it receives from any Other
Licensees without restrictions on disclosure of such Information), as such
Information becomes available, for use in IntraBiotics' Development efforts.
IntraBiotics shall be permitted to use and reference all BioSearch and any Other
Licensee reports provided to IntraBiotics pursuant to this Agreement in any Drug
Approval Application for Licensed Products in the Territory. Notwithstanding the
foregoing, IntraBiotics
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
6.
agrees that it shall treat all Information provided by BioSearch or any Other
Licensee pursuant to this Section 2.3 as Confidential Information, subject to
the terms of Article 9.
(b) TECHNICAL ASSISTANCE. BioSearch shall provide reasonable
technical assistance to IntraBiotics for Development of Licensed Products.
(c) SUPPLY OF CLINICAL MATERIALS. BioSearch shall use [*]
efforts to supply, or cause to be supplied amounts of Bulk Licensed Compound
sufficient for IntraBiotics to obtain Regulatory Approval of Licensed Products
in the Field and in the Territory as set forth in Article 7.
(d) SCALE UP OF MANUFACTURING PROCESS. BioSearch shall use
diligent efforts to scale up its manufacturing process for Bulk Licensed
Compound, at BioSearch's sole expense.
2.4 REPORTS; PROJECT LEADERS. Each Party shall provide to the other
Party reports summarizing such Party's development (including scale-up of the
manufacturing process for Bulk Licensed Compound performed pursuant to Sections
2.3 and 7.3) and commercialization of products containing the Licensed Compound.
Such reports will be provided by each Party within [*] after the end of each
calendar quarter and shall summarize such Party's efforts during the previous
quarter. Additionally, each Party shall, within [*] after the Effective Date,
appoint a project leader to facilitate transfer of information regarding the
Licensed Compound and Licensed Products to the other Party. The project leaders
shall meet on a quarterly basis, and each Party may send one or more additional
representatives to each such meeting. Each Party shall bear all costs incurred
by its project leader and other representative(s) with respect to their
attendance of such meetings. The site of the project leader meetings shall
alternate between IntraBiotics' facility in Mountain View, California and
BioSearch's facility in Gerenzano, Italy.
2.5 ADVERSE EVENT REPORTING. Each Party agrees to report to the other,
immediately upon receipt of the information by such Party, any serious adverse
event which is reported to occur in connection with the use of a Licensed
Product or the Licensed Compound. Each Party agrees to provide to the other
copies of all reports that are made to regulatory authorities concerning
material safety, efficacy or quality matters with respect to any Licensed
Product or the Licensed Compound. Prior to the first Regulatory Approval for a
product containing a Licensed Compound anywhere in the world, the Parties shall
agree on a formal adverse event reporting protocol to conform with the
respective regulatory obligations of IntraBiotics, BioSearch, and any Other
Licensees throughout the world.
2.6 OTHER LICENSEES.
(a) BioSearch agrees to [*] from any Other Licensees
permission for BioSearch to provide to IntraBiotics any information that, if
such information were owned or Controlled by BioSearch, would be Information
that BioSearch must provide to IntraBiotics pursuant to Section 2.3, and shall
endeavor to [*] as provided in Section 5.7(c). BioSearch will require the Other
Licensees to provide to IntraBiotics, either directly or through BioSearch, all
information owned or
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
7.
Controlled by such Other Licensee that, if such information were owned or
Controlled by BioSearch, would be Information that BioSearch must provided to
IntraBiotics pursuant to Section 2.5. BioSearch may provide any Information it
receives from IntraBiotics pursuant to Section 2.5 to the Other Licensees, if
any, and may grant to Other Licensees a sublicense under the license granted to
BioSearch in Section 5.4 with respect to Information BioSearch receives from
IntraBiotics pursuant to Section 2.5.
(b) BioSearch shall not provide any Information it receives
from IntraBiotics pursuant to this Article 2 (other than Information relating to
adverse events provided by IntraBiotics pursuant to Section 2.5) to any Other
Licensee unless and until (i) such Other Licensee permits BioSearch to provide
to IntraBiotics any and all information owned or Controlled by such Other
Licensee that, if such information were owned or Controlled by BioSearch, would
be Information that BioSearch must provide to IntraBiotics pursuant to Section
2.3, and (ii) such Other Licensee has paid to IntraBiotics an amount equal to
[*]. BioSearch may not grant to any Other Licensee a sublicense under the
license granted to BioSearch in Section 5.4 with respect to Information
disclosed to it by IntraBiotics pursuant to this Article 2 (other than
Information relating to adverse events provided by IntraBiotics pursuant to
Section 2.5) to any Other Licensee that does not allow BioSearch to provide to
IntraBiotics information of such Other Licensee as provided in this Section 2.6,
and any such Other Licensee shall not have a right of reference as provided in
2.2.
ARTICLE 3
EXCLUSIVITY
3.1 DEVELOPMENT OF LICENSED COMPOUNDS BY BIOSEARCH. The Parties
recognize that the Licensed Compound may be useful both within and outside of
the Field. In this regard, the Parties agree as follows:
(a) BioSearch, its Affiliates and other sublicensees shall not
develop or commercialize the Licensed Compound in any formulation other than an
Excluded Formulation in the Territory for use in the Field during the term of
this Agreement.
(b) BioSearch, its Affiliates and other sublicensees may
develop and commercialize the Licensed Compound in any formulation for any use
outside of the Territory, and in any Excluded Formulation for any use in the
Field and in the Territory during the term of this Agreement.
ARTICLE 4
LICENSING FEE; MILESTONE PAYMENTS
4.1 LICENSING FEE. As partial payment for the patent licenses
granted by BioSearch pursuant to Article 5 of this Agreement, IntraBiotics
shall (i) pay to BioSearch, within three (3) days after the Effective Date,
one million dollars ($1,000,000) and (ii) issue to BioSearch, within ten (10)
days after the Effective Date,
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
8.
250,000 shares of IntraBiotics Series F Preferred Stock pursuant to a stock
purchase agreement substantially in the form provided by IntraBiotics to
BioSearch prior to the Effective Date.
4.2 MILESTONE PAYMENTS. IntraBiotics or its sublicensee shall make
the following milestone payments to BioSearch within sixty (60) business days
after the first achievement of each of the following milestones with respect
to Licensed Products in the Field and in the Territory. Any grant by
IntraBiotics of a sublicense to a Third Party as permitted in Section 5.5
shall not affect BioSearch's right to receive milestone payments as provided
in this Section 4.2. IntraBiotics shall remain responsible for the payments
due to BioSearch pursuant to this Section 4.2 in the event it grants any such
sublicense. The following amounts are nonrefundable and noncreditable.
MILESTONE PAYMENT
------------------------------------------------------------------ ------------------------------
(i) Commencement of the Phase II Clinical Trials in the United States $[ *]
(ii) Commencement of the Phase III Clinical Trials in the United $[ *]
States
(iii) Filing of the first NDA for a Licensed Product in the United $[ *]
States
(iv) The first Regulatory Approval in the United States of a Licensed $[ *]
Product in [*] formulation
(v) The first Regulatory Approval in the United States of a Licensed $[ *]
Product in a formulation [*]
(vii) The first Regulatory Approval of a Licensed Product in Canada $[ *]
* If IntraBiotics provides to BioSearch the [*] conducted in the
United States prior to [*], the amount due to BioSearch for milestone (iv) shall
be reduced to [*]. IntraBiotics shall not be responsible for any milestone
payment set forth above if IntraBiotics gives notice of termination of this
Agreement under Sections 11.2 or 11.3 prior to the date the milestone is due.
ARTICLE 5
LICENSES
5.1 PATENT LICENSES TO INTRABIOTICS. BioSearch hereby grants to
IntraBiotics an exclusive (even as to BioSearch) license under the BioSearch
Patents to make, have made, use, import, offer, sell, offer for sale and have
sold Licensed Products in the Field and in the Territory. Such license shall not
include the right to make or have made Bulk Licensed Compound unless
IntraBiotics elects to manufacture Bulk Licensed Compound as provided in
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
9.
Section 7.2. Such license shall be subject to the terms and conditions of this
Agreement, including payment of the amounts set forth in Articles 4, 7 and 8
hereof.
5.2 PATENT LICENSES TO BIOSEARCH. IntraBiotics hereby grants to
BioSearch an exclusive (even as to IntraBiotics), paid-up license under
IntraBiotics Patents to make, have made, use, import, offer, sell, offer for
sale and have sold (i) inside the Territory, products containing the Licensed
Compound (including without limitation Licensed Products) for any and all uses
outside of the Field, (ii) inside the Territory, products containing the
Licensed Compound in any Excluded Formulation for any and all uses within the
Field, and (iii) outside of the Territory, products containing the Licensed
Compound (including without limitation Licensed Products) for any and all uses.
5.3 KNOW-HOW LICENSE TO INTRABIOTICS. Subject to Article 9, BioSearch
grants to IntraBiotics a paid-up, nonexclusive license to use BioSearch Know-how
within the Territory for any purpose consistent with the rights and obligations
contained in this Agreement.
5.4 KNOW-HOW LICENSE TO BIOSEARCH. Subject to Article 9, IntraBiotics
grants to BioSearch a paid-up, nonexclusive worldwide license to use
IntraBiotics Know-how for any purpose consistent with the rights and obligations
contained in this Agreement.
5.5 SUBLICENSING. IntraBiotics may grant sublicenses under this Article
5 without the consent of BioSearch to its Affiliates or to Third Parties as
necessary to conduct Development and Commercialization of Licensed Products
within the Field and within the Territory. IntraBiotics will provide to
BioSearch reasonable notice in the event IntraBiotics intends to grant a
sublicense pursuant to this Section 5.5. BioSearch may grant sublicenses under
this Article 5 without the consent of IntraBiotics to its Affiliates within the
scope of licenses granted under IntraBiotics Patents or IntraBiotics Know-how,
respectively. Subject to Section 5.7, BioSearch may grant sublicenses to Other
Licensees within the scope of license granted under Section 5.4 solely to the
extent necessary to allow Other Licensees to use IntraBiotics' Information as
permitted under Article 2.
5.6 RIGHT OF NEGOTIATION FOR [*] FORMULATIONS OF THE LICENSED COMPOUND.
If BioSearch wishes to offer to any Third Party the opportunity to participate
in the research, development and commercialization of products including any [*]
formulation of the Licensed Compound for any indication in the Field and in the
Territory, BioSearch shall, prior to the time it first makes any such offer to a
Third Party, notify IntraBiotics of its intention to enter into such
discussions. If IntraBiotics requests within the [*] period following its
receipt of such notice to discuss with BioSearch the terms upon which
IntraBiotics may research, develop and commercialize in the Territory the
Licensed Compound in a [*] formulation, (either solely or jointly with
BioSearch), then the Parties shall meet and negotiate in good faith the
potential terms of an agreement on such terms. If the Parties do not enter into
such an agreement within [*] after IntraBiotics so requests to negotiate such
opportunity with BioSearch, then BioSearch shall thereafter be free to offer
such opportunity to a Third Party with respect to such [*] formulation of the
Licensed Compound; provided, however, that BioSearch must provide to
IntraBiotics any information that BioSearch provides to any Third Party that
materially differs
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
10.
from the information that BioSearch provided to IntraBiotics with respect
thereto, in which case IntraBiotics may again exercise its right of negotiation
under this Section 5.6. However, BioSearch shall not be obligated to negotiate
or enter into any agreement, either with a Third Party or with IntraBiotics,
with respect to the research, development and commercialization of any such
products.
5.7 THIRD PARTY TECHNOLOGY.
(a) The licenses granted under Article 5, to the extent they
include sublicenses of Third Party technology, shall be subject to the terms and
conditions of the license agreement pursuant to which such sublicense is
granted. BioSearch represents to IntraBiotics that no Third Party technology is
included in the BioSearch Patents or in the BioSearch Know-how as of the
Effective Date.
(b) Any royalties payable to Third Parties in connection with
the sale of Licensed Products in the Territory shall be allocated as provided in
Section 8.2.
(c) BioSearch will endeavor to assist IntraBiotics in
obtaining access to, and licenses under, technology relating to Licensed
Products that is owned or Controlled by any Other Licensee which is developing
or commercializing products containing the Licensed Compound (including without
limitation Licensed Products) outside of the Territory, or products containing
the Licensed Compound (including without limitation Licensed Products) within
the Territory, in each case solely to the extent such technology is necessary or
useful for the Development or Commercialization of Licensed Products in the
Field.
ARTICLE 6
COMMERCIALIZATION
6.1 GENERAL. The Commercialization of Licensed Products in the Field
and in the Territory shall be conducted independently by IntraBiotics and its
Affiliates.
6.2 INTRABIOTICS EFFORTS. IntraBiotics will use [*] to promote, sell
and distribute the Licensed Products in the Territory after it obtains
Regulatory Approval therefor, consistent with accepted business practices.
6.3 FORMULATION, PACKAGING AND LABELING. IntraBiotics will be
responsible for formulating Bulk Licensed Compound into final dosage form and
packaging the Licensed Product for sale under this Agreement, including, without
limitation, designing and producing all packaging materials and product inserts,
all in forms consistent with the requirements of the regulatory authorities in
the Territory.
6.4 EXPENSES. All expenses incurred by IntraBiotics in connection
with its obligations under this Article 6 will be borne solely by
IntraBiotics. IntraBiotics will be responsible for appointing its own
employees, agents and representatives, who will be compensated by
IntraBiotics.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
11.
6.5 RESTRICTIONS ON DISTRIBUTORS AND DEALERS. BioSearch shall not, and
shall also insure that any of its distributors or dealers (including its
Affiliates and non-Affiliates) to whom BioSearch sells products containing the
Licensed Compound (including without limitation Licensed Products) for resale
shall not, sell the Licensed Product for use in the Field to any customer
located in the Territory.
6.6 PRICING. IntraBiotics shall determine, in its sole discretion, the
pricing, discounting policy and other commercial terms relating to Licensed
Products in the Field and in the Territory.
ARTICLE 7
MANUFACTURE AND SUPPLY; TRANSFER PRICE AND SUPPLY PRICE
7.1 MANUFACTURE AND SUPPLY OF BULK LICENSED COMPOUND BY BIOSEARCH.
Subject to the terms and conditions of this Article 7, BioSearch will
manufacture, or arrange for manufacture of, IntraBiotics' requirements of
Bulk Licensed Compounds for Development and Commercialization of Licensed
Products in the Field and in the Territory (unless IntraBiotics elects also
to manufacture Bulk Licensed Compound as permitted under this Article 7),
subject to the payment of a Transfer Price for preclinical and clinical
supply pursuant to Section 7.9 and a Supply Price for commercial supply as
provided in Section 8.2. IntraBiotics, at its sole expense, will be
responsible for having the Bulk Licensed Compound that is manufactured by
BioSearch pursuant to this Article 7 processed into the final form of
Licensed Product for commercial sale in the Field.
7.2 MANUFACTURE BY INTRABIOTICS. Although the Parties intend that
BioSearch shall supply IntraBiotics' requirements of Bulk Licensed Compound,
BioSearch recognizes that IntraBiotics may desire to establish a second
manufacturing capability for Bulk Licensed Compound, at IntraBiotics' own
cost, as protection against possible disruptions to supply. IntraBiotics may
elect to perform all of the manufacture of its forecasted requirements of
Bulk Licensed Compound either if BioSearch is unable or unwilling to meet its
supply obligations as outlined in this Article 7, if BioSearch ceases
development and scale-up of manufacturing of the Bulk Licensed Compound, or
as set forth in Section 8.2(c). BioSearch shall provide prompt notice to
IntraBiotics either if BioSearch anticipates that it will be unable to meet
IntraBiotics' forecasted or actual requirements for Bulk Licensed Compound,
or if BioSearch intends to cease development and scale-up of manufacturing of
the Bulk Licensed Compound. If IntraBiotics manufactures Bulk Licensed
Compound pursuant to this Section 7.2, then IntraBiotics shall pay to
BioSearch a royalty equal to the average Royalty (as defined in Section 8.2)
paid to BioSearch on Net Sales during the twelve (12) months preceding the
commencement of IntraBiotics' manufacture of the Bulk Licensed Compound [*]
pursuant to Section 8.2. If IntraBiotics elects to manufacture Bulk Licensed
Compound, then BioSearch shall be relieved of its obligation to supply Bulk
Licensed Compound, although the Parties may then separately agree that
BioSearch may continue to supply a portion of IntraBiotics' requirements of
Bulk Licensed Compound. Upon IntraBiotics' request, BioSearch shall, and
shall cause its manufacturing contractors to, transfer to IntraBiotics or its
designee, and fully enable IntraBiotics or its designee with the then most
current version of
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
12.
all biological materials, know-how, and expertise necessary to manufacture
the Bulk Licensed Compound, including all production and quality control
specifications. BioSearch shall periodically update such materials.
IntraBiotics may use such materials to manufacture Bulk Licensed Compounds
only as provided in this Agreement. (In regard to the foregoing, the Parties
agree to cooperate to obtain all necessary assurances and cooperation from
any of BioSearch's Third Party contract manufacturers.) If IntraBiotics
elects to manufacture Bulk Licensed Compounds, BioSearch shall promptly
provide to IntraBiotics all process and manufacturing technology, material
and data and provide access to regulatory filings sufficient to enable
IntraBiotics to produce its requirements of such Bulk Licensed Compound. In
addition, BioSearch shall provide a right of reference and access to
appropriate regulatory filings for the manufacture of such Bulk Licensed
Compound to IntraBiotics.
7.3 PROCESS DEVELOPMENT, MANUFACTURING APPROVALS. BioSearch will use
[*] efforts to develop a process for the manufacture of Bulk Licensed Compounds
according to the specifications therefor and to scale up that process to a scale
sufficient to manufacture and supply IntraBiotics' anticipated requirements for
clinical and commercial supply of Licensed Products. BioSearch will use [*]
efforts to make necessary filings to obtain, or to cause a Third Party
manufacturer of Bulk Licensed Compounds to make necessary filings to obtain,
Regulatory Approval for the manufacture of Bulk Licensed Compounds as part of
the approval of a Drug Approval Application for each Licensed Product in the
Field and in the Territory.
7.4 SPECIFICATIONS. The current specifications for Bulk Licensed
Compound are attached to this Agreement in Exhibit 7.4. Either Party may at any
time during the term of this Agreement propose to the other Party changes to the
specifications for Bulk Licensed Compound. The Parties may during the term of
this Agreement modify the specifications for Bulk Licensed Compound if
regulatory authorities within the Territory recommend or require changes
thereto, or if one Party submits a proposal for changing such specifications to
the other Party and the other Party agrees to such changes. Either Party shall
give prior notice to the other of any changes in the specifications for Bulk
Licensed Compound that are recommended or required by the regulatory authorities
within the Territory. Any material changes to the specifications for Bulk
Licensed Compound may not be made without prior written consent of both Parties.
Notwithstanding the previous sentence, both Parties shall use their [*] efforts
to implement changes in the specifications which are required by the regulatory
authorities within the Territory unless both Parties agree to the contrary in
writing. At the request of IntraBiotics, BioSearch shall arrange for
IntraBiotics' designated representatives to inspect and visit from time to time
the facilities at which Bulk Licensed Compound is manufactured, stored or tested
for the purpose of determining that the manufacture of Bulk Licensed Compound
complies with the requirements of this Agreement. Such inspections shall occur
during regular business hours upon reasonable notice.
7.5 FORECASTING. IntraBiotics will provide BioSearch with rolling
forecasts of its expected requirements of Bulk Licensed Compound over the [*]
following the Effective Date on a [*] basis. Such forecasts shall set forth (i)
IntraBiotics' actual requirements for Bulk Licensed Compound for the following
[*], which portion of the forecast shall be binding and serve as an order for
Bulk Licensed Compound, and (ii) IntraBiotics' best estimate of its requirements
for
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
13.
the following [*] quarters. In no event shall BioSearch be required to deliver
more Bulk Licensed Compound in any given quarter than was estimated for such
quarter in the last [*] applicable forecasts. In addition, except with the
written consent of BioSearch, IntraBiotics may not increase its forecast of any
material requirements in a particular calendar quarter by more than [* ] of its
forecast for such quarter as set forth in the immediately preceding forecast for
such quarter. However, BioSearch shall use [*] efforts to supply any additional
quantities requested by IntraBiotics in excess of the amounts previously
forecasted by IntraBiotics, it being recognized that substantial increases in
production levels may require significant advance notice.
7.6 SHIPMENT OF BULK LICENSED COMPOUND. BioSearch shall ship Bulk
Licensed Compound it manufactures for IntraBiotics pursuant to this Article 7 to
location(s) designated by IntraBiotics by such method and carrier as
IntraBiotics shall request. Unless otherwise agreed by the Parties, all
shipments of Bulk Licensed Compound by BioSearch shall be [*] to a mutually
agreed delivery site within the Territory. BioSearch shall use [*] efforts to
deliver Bulk Licensed Compound on the dates specified by IntraBiotics. BioSearch
will bear all transportation expenses for the delivery of material to
IntraBiotics, and shall bear all risk of loss of any material following shipment
from the place of manufacture until delivered to IntraBiotics.
7.7 INVOICES. BioSearch will invoice IntraBiotics for each batch of
material supplied to IntraBiotics under this Article 7 and accepted by
IntraBiotics as provided in Section 7.8. IntraBiotics shall pay such invoices
within [*] after its receipt thereof.
7.8 ACCEPTANCE. Upon receipt of a shipment of Bulk Licensed Compound
from BioSearch, IntraBiotics may determine whether such shipment meets the
specifications. IntraBiotics shall notify BioSearch in writing promptly if such
Bulk Licensed Compound manufactured by BioSearch fails to meet the
specifications therefor. If BioSearch has not received such written notice
within [*] after such material has been received by IntraBiotics, then such
shall be deemed to have met the specifications. Upon receipt of any such written
notice of non-conformance, BioSearch shall either acknowledge that the subject
Bulk Licensed Compound does not meet the specifications or resample the lot or
batch in question and have said samples tested by an independent laboratory
acceptable to IntraBiotics. If such independent laboratory determines that such
samples fail to meet the specifications, then BioSearch shall at IntraBiotics
option either replace the non-conforming Bulk Licensed Compound at no additional
cost as soon as reasonably possible or refund IntraBiotics' payments for such
non-conforming materials.
7.9 TRANSFER PRICE FOR CLINICAL SUPPLY. Prior to receipt of Regulatory
Approval of the Licensed Product in the Territory, IntraBiotics will purchase
clinical supplies of Bulk Licensed Compound at a price (the "Transfer Price")
equal to [*] for such Bulk Licensed Compound.
7.10 MANUFACTURING REPORTS. The reports that BioSearch shall provide to
IntraBiotics pursuant to Section 2.4 shall include a summary of BioSearch's
efforts to scale up the manufacturing process for Bulk Licensed Compound
pursuant to Section 2.3.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
14.
7.11 RETENTION OF BACK-UP SUPPLY OF BULK LICENSED COMPOUND. To help
protect against interruptions in supply of Bulk Licensed Compounds pursuant to
this Article 7, BioSearch shall retain under appropriate conditions a [*] supply
of Bulk Licensed Compound at all times after the parties commence production of
Licensed Products for commercial launch. IntraBiotics shall notify BioSearch at
least [*] prior to commencement of commercial scale manufacture of Bulk Licensed
Compound of the amount of Bulk Licensed Compound that constitutes a [*] supply
for the purpose of this Section 7.11 (the "Retained Amount"). IntraBiotics may
re-establish the Retained Amount from time to time as necessary or desirable in
view of its good faith estimate of its requirements for Bulk Licensed Compounds
during the remainder of the term of this Agreement.
7.12 DISCUSSIONS REGARDING LONG TERM SUPPLY CAPACITY. The parties
acknowledge that IntraBiotics will gain knowledge regarding the potential market
for Licensed Products in the Field and in the Territory as the development of
Licensed Products progresses. Accordingly, it is possible that IntraBiotics'
full commercial requirements for Bulk Licensed Compounds either upon commercial
launch of Licensed Products or thereafter may exceed the capacity at BioSearch's
manufacturing facility therefor. If at any time IntraBiotics' good faith
estimate of the market for Licensed Products indicates that BioSearch's current
manufacturing facility may not have sufficient capacity for manufacturing
IntraBiotics' requirements for Bulk Licensed Compound over the term of this
Agreement, then IntraBiotics and BioSearch shall discuss in good faith
acceptable mechanisms for any such actual or potential inability of BioSearch to
supply IntraBiotics' requirements, which may include without limitation for the
establishment of a second manufacturing site by BioSearch. If the parties do not
agree on such mechanisms for assuring sufficient supply of Bulk Licensed
Compound and appropriate amendments to this Agreement implementing such
mechanisms, then IntraBiotics may elect to establish a second manufacturing site
as provided in Section 7.2 or to pursue other remedies available to it under law
or in equity or under this Agreement.
ARTICLE 8
SUPPLY PRICE PAYMENTS; PAYMENT PROCEDURES; RECORDS
8.1 SUPPLY OBLIGATION; DURATION. During the term of this Agreement,
IntraBiotics shall purchase all of its requirements for Bulk Licensed Compound
from BioSearch, subject to Section 7.2. The price for commercial supply to
IntraBiotics of all Bulk Licensed Compound manufactured by BioSearch shall be as
provided in Section 8.2.
8.2 SUPPLY PRICE.
(a) IntraBiotics will pay to BioSearch a price for commercial
supply of Bulk Licensed Compounds by BioSearch (a "Supply Price") that will have
two components, a transfer price (the "Transfer Price") and a royalty payment
(the "Royalty"). The Transfer Price will be equal to the greater of (i) [*], or
(ii) [*] of Bulk Licensed Compound. Subject to Section 8.2(b), the Royalty will
be equal to [*] subject to the following adjustment: if the Transfer Price
exceeds [*] of Licensed Products, then the Royalty will be reduced by [*] of the
amount by
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
15.
which the Transfer Price exceeds [*]. Any royalties due to Third Parties with
respect to the manufacture, use, sale, offer for sale or import of Licensed
Products in the Field and in the Territory shall be borne solely by BioSearch.
(b) If a generic form of a Licensed Product is introduced by a
Third Party in any country in the Territory in which the manufacture, use, sale,
offer for sale and import of a Licensed Product by a Third Party would not
infringe a Valid Claim of a BioSearch Patent, then the Royalty portion of the
Supply Price due to BioSearch pursuant to Section 8.2(a) shall be reduced to [*]
in such country.
(c) In the event that the sum of the Supply Price payments due
to BioSearch pursuant to Sections 8.2(a) and (b), and the costs incurred by
IntraBiotics or its sublicensee in manufacturing Licensed Product from Bulk
Licensed Compound supplied by BioSearch and performing labeling and packaging of
such Licensed Products (such sum referenced herein as "Total Costs") is greater
than [*] for more than [*] consecutive calendar quarters, then the Parties
shall, promptly after request by IntraBiotics, meet and discuss in good faith an
appropriate mechanism to reduce the Total Costs. If the Parties do not agree
upon such an appropriate mechanism within [*] after IntraBiotics requests a
meeting pursuant to this Section 8.2(c), then IntraBiotics may elect to
manufacture or have manufactured by a Third Party its requirements of Bulk
Licensed Compound and thereafter pay to BioSearch a royalty equal to the average
Royalty portion of the Supply Price due to BioSearch pursuant to Sections 8.2(a)
and (b) during the [*] immediately preceding IntraBiotics' request for a meeting
pursuant to this Section 8.2(c), notwithstanding Sections 7.2, 8.2(a) or 8.2(b).
8.3 SALES BY SUBLICENSEES. If IntraBiotics grants a sublicense under
the rights granted to it pursuant to Section 5, then such sublicense shall
include an obligation for the sublicensee to account for and report its Net
Sales of such Licensed Products on the same basis as if such sales were Net
Sales by IntraBiotics, and IntraBiotics shall pay the Supply Price to BioSearch
on such sales as if the Net Sales of the sublicensee were Net Sales of
IntraBiotics.
8.4 TRANSFER PRICE PAYMENTS, ROYALTY PAYMENTS AND SUBLICENSE REVENUE
PAYMENTS.
(a) BioSearch shall invoice IntraBiotics for Bulk Licensed
Compound supplied at an estimated transfer price equal to [*] of Bulk Licensed
Compound. IntraBiotics shall pay for such material at such estimated transfer
price within [*] of the invoice date. IntraBiotics will deliver a report showing
in detail its calculation of the Net Sales of any Licensed Products during a
given calendar quarter to BioSearch within [*] following the end of each
calendar quarter and [*] following the end of each calendar year for which
Transfer Price payments are due from IntraBiotics. Any differences between the
total estimated transfer price payments made and the actual Transfer Price
payments due to BioSearch pursuant to Section 8.2 for any quarter shall be
reconciled within [*] following the delivery of such quarterly report.
(b) IntraBiotics will deliver a report showing in detail its
calculation of the Net Sales of any Licensed Products during a given calendar
quarter to BioSearch within [*]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
16.
following the end of each calendar quarter and [*] following the end of each
calendar year for which Royalty or other royalty payments are due from
IntraBiotics. IntraBiotics shall pay the Royalty or other royalty due on Net
Sales for the calendar quarter covered by a given report under this Section
8.4(b) within [*] after IntraBiotics provides such report to BioSearch.
(c) IntraBiotics will deliver a report showing in detail its
calculation of the Net Sales of any Licensed Products received by IntraBiotics
from its sublicensees during a given calendar quarter to BioSearch within [*]
following the end of each calendar quarter and [*] following the end of each
calendar year for which payments are due from IntraBiotics to BioSearch thereon.
IntraBiotics shall pay the amounts due to BioSearch on Net Sales by
IntraBiotics' sublicensees pursuant to Section 8.2 and 8.3 for a given calendar
quarter covered by such reports within [*] after IntraBiotics provides such
report to BioSearch.
8.5 EXCHANGE RATE: MANNER AND PLACE OF PAYMENT. All amounts paid to
BioSearch hereunder shall be paid in United States currency. Net Sales shall be
accounted for on a monthly basis in U.S. Dollars for each month on the last
banking day of such month. All payments due to BioSearch under this Agreement
shall be made by wire transfer at a bank and to an account designated by
BioSearch, unless otherwise specified by BioSearch.
8.6 LATE PAYMENTS. In the event that any payment due hereunder is not
made when due, the payment shall accrue interest from the date due at the rate
of [* ] per month; provided that in no event shall such rate exceed the maximum
legal annual interest rate. The payment of such interest shall not limit any
Party from exercising any other rights it may have as a consequence of the
lateness of the payment.
8.7 RECORD KEEPING. During the term of this Agreement, IntraBiotics
shall keep full and accurate books and records setting forth, for the
Licensed Product on which Supply Price payments are due, including gross
sales, all deductions allowed in arriving at Net Sales and any other
information necessary and in sufficient detail to allow the calculation of
Supply Price payments to be paid by IntraBiotics. During the term of this
Agreement and for a period of three (3) years thereafter, IntraBiotics shall
permit BioSearch, at BioSearch's expense, by independent certified public
accountants employed by BioSearch and reasonably acceptable to IntraBiotics,
to examine relevant books and records at any reasonable time, not more often
than once each calendar year, within five (5) years of the payment of such
Supply Price. If it is determined that there was an underpayment of Supply
Price due BioSearch of [* ] or more, without prejudice to any other rights
BioSearch may have, IntraBiotics shall promptly pay to BioSearch the balance
of the amounts due and shall also reimburse BioSearch for the cost of such
verification examination.
8.8 TAX AND WITHHOLDINGS. Any withholding taxes levied by tax
authorities in the Territory on the payments hereunder shall be borne by
BioSearch and deducted by IntraBiotics from the sums otherwise payable by it
hereunder for payment to the proper tax authorities on behalf of BioSearch. In
such event, IntraBiotics shall deliver to BioSearch evidence of the payment of
such taxes. IntraBiotics agrees to cooperate with BioSearch in the event
BioSearch claims exemption from such withholding or seeks deductions under any
double taxation or other similar treaty or agreement from time to time in force.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
17.
ARTICLE 9
CONFIDENTIALITY
9.1 CONFIDENTIALITY; EXCEPTIONS. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that, for the term of this Agreement and for five (5) years thereafter, the
receiving Party shall keep confidential and shall not publish or otherwise
disclose or use for any purpose other than as provided for in this Agreement any
Information and other information and materials furnished to it by the other
Party pursuant to this Agreement, or any provisions of this Agreement that are
the subject of an effective order of the Securities Exchange Commission granting
confidential treatment pursuant to the Securities Act of 1934, as amended
(collectively, "Confidential Information"), except to the extent that it can be
established by the receiving Party that such Confidential Information:
(a) was already known to the receiving Party, other than under
an obligation of confidentiality, at the time of disclosure by the other Party;
(b) was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving Party;
(c) became generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement; or
(d) was disclosed to the receiving Party, other than under an
obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others.
9.2 AUTHORIZED DISCLOSURE. Each Party may disclose Confidential
Information hereunder to the extent such disclosure is reasonably necessary in
filing or prosecuting patent applications, prosecuting or defending litigation,
complying with applicable governmental regulations or conducting preclinical or
clinical trials, provided that if a Party is required by law or regulation to
make any such disclosure of the other Party's Confidential Information it will,
except where impracticable for necessary disclosures (for example in the event
of medical emergency), give reasonable advance notice to the other Party of such
disclosure requirement and, except to the extent inappropriate in the case of
patent applications, will use its [*] to secure confidential treatment of such
Confidential Information required to be disclosed. In addition, each Party shall
be entitled to disclose, under a binder of confidentiality containing provisions
as protective as those of this Article 9, Confidential Information to any Third
Party for the purpose of carrying out activities authorized under this
Agreement, including disclosures to authorized sublicensees, and subject to
Sections 2.5 and 2.6 disclosures by BioSearch for purposes of the development
and commercialization of products other than Licensed Products anywhere in the
world outside of the Field, and of Licensed Products either outside of the Field
and within the Territory, or within the Field and outside of the Territory.
Nothing in this Article 9 shall restrict any Party from using for any purpose
any Information developed by it during the course of the
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
18.
collaboration hereunder. BioSearch acknowledges that if IntraBiotics files a
registration statement covering the sale of its securities in the United States,
it will be required to file a copy of this Agreement with its public disclosure
statement. IntraBiotics agrees to seek confidential treatment of at least the
economic terms of this Agreement with respect to any such filing.
9.3 SURVIVAL. This Article 9 shall survive the termination or
expiration of this Agreement for a period of five (5) years.
9.4 TERMINATION OF PRIOR AGREEMENT. This Agreement supersedes the
Confidentiality Agreement between BioSearch and IntraBiotics dated May 23, 1997.
All Information exchanged between the Parties under that Agreement shall be
deemed Confidential Information and shall be subject to the terms of this
Article 9, and shall be included within the definitions of BioSearch Know-how
and IntraBiotics Know-how.
9.5 PUBLICATIONS. Except as required by law, each Party agrees that it
shall not publish or present Information relating to the Licensed Compound or to
products containing the Licensed Compound without providing to the other Party
the opportunity for prior review of such publication or presentation. The Party
desiring to publish or present such Information (the "Proposing Party") shall
provide to the other Party the opportunity to review such proposed publication
or presentation (including information to be presented verbally) as early as
reasonably practical, but not later than twenty (20) days prior to the
anticipated date of submission or disclosure to a Third Party. The Party
reviewing such publication or presentation shall respond to the Proposing Party
with comments thereon within ten (10) days of receiving such materials from the
Proposing Party. The Proposing Party agrees, upon written request from the other
Party, not to submit such abstract or manuscript for publication or to make such
presentation until the other Party consents, which agreement shall not be
unreasonably withheld.
ARTICLE 10
OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS
10.1 OWNERSHIP. Each Party shall solely own, and it alone shall have
the right to apply for, Patents within and outside of the Territory for any
inventions made solely by that Party's employees or consultants in the course of
performing work under this Agreement. Inventions made jointly by personnel of
BioSearch and IntraBiotics shall be jointly owned by the Parties, subject to the
licenses granted to IntraBiotics pursuant to Article 5.
10.2 DISCLOSURE OF PATENTABLE INVENTIONS. Each Party shall provide to
the other any patent application disclosing an invention relating to Licensed
Products within the Field arising during the term of this Agreement. Such patent
applications disclosing inventions made solely by a Party shall be provided to
the other Party promptly after submission of such application to a governmental
Patent authority, which shall in no event be later than [*] days after the date
the disclosure was submitted. Any such patent applications disclosing inventions
made jointly by the Parties shall be provided by BioSearch to IntraBiotics
reasonably in advance of the intended date for submission of such application to
a governmental Patent authority.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
19.
10.3 PATENT FILINGS.
(a) BIOSEARCH RESPONSIBILITIES. BioSearch shall prepare, file,
prosecute and maintain Patents to cover inventions relating to the discovery,
evaluation, manufacture, use or sale of Licensed Products that are made solely
by BioSearch personnel (all of which shall be included in BioSearch Patents) or
that are made jointly by personnel of BioSearch and IntraBiotics in the course
of the collaboration ("Joint Patents," all of which shall be included in both
the BioSearch Patents and IntraBiotics Patents). BioSearch shall keep
IntraBiotics informed of the status of each BioSearch Patent and Joint Patent
and shall give reasonable consideration to any suggestions or recommendations of
IntraBiotics concerning the preparation, filing, prosecution and maintenance
thereof. The Parties shall cooperate reasonably in the prosecution of all
BioSearch Patents and Joint Patents under this Section 10.3(a) and shall share
all material Information relating thereto promptly after receipt of such
Information. If, during the term of this Agreement, BioSearch intends to allow
any issued BioSearch Patent or Joint Patent to which IntraBiotics has a license
under this Agreement to expire for failure to make maintenance fee payments,
BioSearch shall notify IntraBiotics of such intention at least [*] prior to the
date upon which such issued BioSearch Patent or Joint Patent shall expire, and
IntraBiotics shall thereupon have the right, but not the obligation, to assume
responsibility for the maintenance thereof.
(b) INTRABIOTICS RESPONSIBILITIES. IntraBiotics shall file,
prosecute and maintain Patents to cover inventions relating to the discovery,
evaluation, manufacture, use or sale of Licensed Products that are made solely
by IntraBiotics personnel (all of which shall be included in IntraBiotics
Patents). IntraBiotics shall keep BioSearch informed of the status of each
IntraBiotics Patent and shall give reasonable consideration to any suggestions
or recommendations of BioSearch concerning the preparation, filing, prosecution
and maintenance thereof. The Parties shall cooperate reasonably in the
prosecution of all IntraBiotics Patents under this Section 10.3(b) and shall
share all material Information relating thereto promptly after receipt of such
Information. If, during the term of this Agreement, IntraBiotics intends to
allow any issued IntraBiotics Patent to which BioSearch has a license under this
Agreement to expire for failure to make maintenance fee payments, IntraBiotics
shall notify BioSearch of such intention at least [*] prior to the date upon
which such IntraBiotics Patent shall expire, and BioSearch shall thereupon have
the right, but not the obligation, to assume responsibility for the maintenance
thereof.
10.4 THIRD PARTY PATENT RIGHTS. No Party makes any warranty with
respect to the validity, perfection or dominance of any Patent or other
proprietary right or with respect to the absence of rights in Third Parties
which may be infringed by the manufacture or sale of the Licensed Product. Each
Party agrees to bring to the attention of the other Party any patent or patent
application it discovers, or has discovered, and which relates to the subject
matter of this Agreement.
10.5 ENFORCEMENT RIGHTS.
(a) INFRINGEMENT BY THIRD PARTIES. If any BioSearch Patent or
IntraBiotics Patent is infringed by a Third Party in the Territory in connection
with the manufacture, import,
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
20.
use, sale or offer for sale of a product competitive with a Licensed Product
("Competitive Product Infringement"), the Party to this Agreement first
having knowledge of such infringement shall promptly notify the other in
writing. The notice shall set forth the facts of that infringement in
reasonable detail. IntraBiotics shall have the primary right, but not the
obligation, to institute, prosecute or control any action or proceeding with
respect to such infringement of a BioSearch Patent (including Joint Patents)
within the Field and within the Territory, or of an IntraBiotics Patent other
than a Joint Patent anywhere in the world both within and outside of the
Field, by counsel of its own choice. BioSearch shall have the right to
participate in such action and to be represented by counsel of its own
choice. BioSearch shall have the primary right, but not the obligation, to
institute, prosecute, and control any action or proceeding with respect to
such infringement of BioSearch Patents (including Joint Patents) occurring
within the Territory that is outside of the Field, or occurring anywhere else
in the world both within and outside of the Field, by counsel of its own
choice. Solely within the Territory with respect to BioSearch Patents other
than Joint Patents and anywhere in the world with respect to Joint Patents,
IntraBiotics shall have the right to participate in such action brought by
BioSearch pursuant to the foregoing sentence and to be represented by counsel
of its own choice therein. If the Party primarily responsible for bringing
suit under this Section 10.5(a) (the "Responsible Party") fails to bring an
action or proceeding within a period of ninety (90) days after having
knowledge of that infringement, then, solely with respect to infringement
occurring inside the Field and inside the Territory with respect to
infringement of patents other than Joint Patents and anywhere in the world
with respect to infringement of Joint Patents, the other Party shall have the
right to bring and control any such action by counsel of its own choice, and
the Responsible Party shall have the right to participate in such action and
be represented by counsel of its own choice. If a Responsible Party brings
any such action or proceeding hereunder, the other Party agrees to be joined
as a party plaintiff and to give the Responsible Party reasonable assistance
and authority to control, file and prosecute the suit as necessary. The costs
and expenses of the Party bringing suit under this Section (including the
internal costs and expenses specifically attributable to said suit) shall be
reimbursed first out of any damages or other monetary awards recovered in
favor of the Parties. Any remaining damages shall be [* ] to BioSearch and [*]
to IntraBiotics. No settlement or consent judgment or other voluntary final
disposition of a suit under this Section 10.5(a) may be entered into without
the joint consent of BioSearch and IntraBiotics.
(b) DEFENSE AND SETTLEMENT OF THIRD PARTY CLAIMS AGAINST
LICENSED PRODUCTS. If a Third Party asserts that a patent or other right owned
by it is infringed by the manufacture, import, use, sale or offer for sale of
any Licensed Product, the Party first obtaining knowledge of such a claim shall
immediately provide the other Party notice of such claim and the related facts
in reasonable detail. Defense of any such claim in the Field and in the
Territory shall be controlled by IntraBiotics; provided that BioSearch shall
have the right to participate in such defense and to be represented in any such
action by counsel of its selection at its sole discretion. IntraBiotics shall
also have the right to control settlement of such claim with respect to a
Licensed Product in the Field and in the Territory; PROVIDED, HOWEVER, that no
settlement shall be entered into without the written consent of BioSearch, which
consent shall not be withheld unreasonably.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
21.
(c) ALLOCATION OF EXPENSES INCURRED PURSUANT TO SECTION
10.5(b). The expenses of patent defense, settlement and judgments pursuant to
Section 10.5(b) with respect to the Licensed Products shall be borne solely
by IntraBiotics, except as provided in Section 10.5(d).
(d) SETTLEMENT OF THIRD PARTY CLAIMS FOR INFRINGEMENT;
PAYMENT OF THIRD PARTY ROYALTIES. If a Third Party asserts that a patent or
other right owned by it is infringed by the manufacture, use, sale, offer for
sale or import of any Licensed Product, and as a result of settlement
procedures or litigation under this Section 10.5, IntraBiotics is required to
pay the Third Party a royalty or make any payment of any kind for the right
to sell a Licensed Product in a particular country, such expense shall be
borne by BioSearch as set forth in Section 8.2.
(e) AGREEMENT OF PRIMARILY RESPONSIBLE PARTY. Notwithstanding
the provisions of Section 10.5(a), neither Party shall file and prosecute an
action for infringement of a Patent for which the other Party has the primary
responsibility to file and prosecute such action, and pursuant to which that
other Party having primary responsibility has commenced and is prosecuting at
least one such action for infringement of said Patent, without the agreement of
that other Party, which agreement shall not be unreasonably withheld.
10.6 PATENT MARKING. IntraBiotics shall xxxx Licensed Products with
appropriate patent numbers or indicia as necessary to maintain the
enforceability of BioSearch Patents, Joint Patents and IntraBiotics Patents.
10.7 TRADEMARKS.
(a) PRODUCT TRADEMARKS. Subject to section 10.7(c),
IntraBiotics shall select, prosecute applications for, register, maintain and
enforce the trademark for Licensed Products in the Territory, at
IntraBiotics' sole expense. All uses of a trademark(s) to identify a Licensed
Product shall comply with all applicable laws and regulations, including
without limitation those laws and regulations particularly applying to the
proper use and designation of trademarks.
(b) INFRINGEMENT. Each Party shall notify the other Party
promptly upon learning of any actual, alleged or threatened infringement of the
trademark for Licensed Product in the Field and in the Territory or of any
unfair trade practices, trade dress imitation, passing off of counterfeit goods
or like offenses. The parties shall confer regarding the appropriate steps
necessary or useful to protect, enforce and maintain such trademark.
IntraBiotics shall make the final decision of whether and how to defend the
trademark.
(c) TRADEMARK LICENSE. If IntraBiotics so requests,
BioSearch shall grant to IntraBiotics a fully paid license to use any
trademarks owned or Controlled by BioSearch under which BioSearch sells and
markets products containing the Licensed Compound (the "BioSearch Marks")
solely in connection with IntraBiotics' Commercialization of Licensed
Products in the Field and in the Territory pursuant to this Agreement.
IntraBiotics may sublicense such rights under the BioSearch Marks only in
connection with a sublicense under the rights granted to IntraBiotics
pursuant to Section 5.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
22.
10.8 TRADE SECRETS. The parties each acknowledge that BioSearch
maintains certain technology useful for the manufacture of the Bulk Licensed
Compound as a trade secret and that accordingly BioSearch has chosen not to seek
patent protection on such technology. BioSearch hereby agrees that it shall use
[*] efforts to maintain such technology as a trade secret (unless and until
BioSearch files a patent application claiming such technology), including
without limitation (i) disclosing such technology to third parties only under an
obligation of confidentiality and non-use with respect thereto comparable in
scope to the confidentiality and non-use obligations set forth in Article 9 with
respect to Confidential Information, (ii) not disclosing any trade secrets in
any public presentation or publication and (iii) employing other mechanisms
typically used in the pharmaceutical industry to protect trade secrets of
similar nature.
ARTICLE 11
TERM AND TERMINATION
11.1 TERM. Except as otherwise provided herein, the term of this
Agreement shall commence on the Effective Date and, unless earlier terminated
as provided in this Agreement, shall expire upon the later of (i) the date
upon which the last to expire of the BioSearch Patents and the IntraBiotics
Patents covering the manufacture, use, sale, offer for sale or import of
Licensed Products in the Field and in the Territory expires, or (ii) ten (10)
years after first commercial sale of a Licensed Product by IntraBiotics in
the Field and in the Territory. After expiration of this Agreement pursuant
to this Section 11.1, IntraBiotics' license under the BioSearch Know-how
shall remain in full force and effect and IntraBiotics may thereafter
continue to sell Licensed Products in the Field and in the Territory on a
royalty-free basis.
11.2 TERMINATION FOR CAUSE. Either Party may terminate this Agreement
upon [*] written notice upon or after the breach of any material provision of
this Agreement by the other Party if the breaching Party has not cured such
breach within the [*] period following written notice of termination by the
other Party.
11.3 OTHER TERMINATION BY INTRABIOTICS. IntraBiotics may terminate this
Agreement, [*], at will at any time prior to the first Regulatory Approval of
Licensed Products in the Territory, effective upon [*] advance written notice to
BioSearch. After IntraBiotics notifies BioSearch of any such termination, no
milestone payments that would otherwise become payable with respect to a
Licensed Product in the country or countries with respect to which IntraBiotics
has so terminated this Agreement shall become payable to BioSearch.
11.4 EFFECT OF TERMINATION.
(a) Upon termination of this Agreement by BioSearch for
IntraBiotics' material breach pursuant to Section 11.2 or by IntraBiotics
pursuant to Section 11.3, all rights and licenses granted to IntraBiotics with
respect to the Licensed Product under Article 5 shall terminate. Furthermore,
upon termination by BioSearch pursuant to Section 11.2 or by IntraBiotics
pursuant to Section 11.3, IntraBiotics shall pay all sums accrued hereunder
which are then due (except as expressly otherwise provided in this Agreement),
and IntraBiotics shall
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
23.
promptly assign to BioSearch all right, title and interest in and to any
regulatory filings in the Territory pertaining to Licensed Products and shall
deliver to BioSearch any IntraBiotics Information necessary to obtain the
Regulatory Approval of Licensed Products in the Territory which has not been
obtained as of the date of termination. If this Agreement is terminated by
BioSearch pursuant to Section 11.2 or by IntraBiotics pursuant to Section 11.3,
IntraBiotics shall return to BioSearch, or at BioSearch' request destroy, all
BioSearch Information and any other Confidential Information relating to the
Licensed Compound or Licensed Products, and any Bulk Licensed Compound supplied
by BioSearch for clinical development or commercial distribution. Additionally,
if BioSearch terminates this Agreement pursuant to Section 11.2 or IntraBiotics
terminates this Agreement pursuant to Section 11.3, the license granted in
Section 5.2 shall automatically become, without any further action by
IntraBiotics, an exclusive, worldwide, royalty-free license under the
IntraBiotics Patents and Joint Patents to make, have made, use, import, offer,
sell, offer for sale and have sold the Licensed Compound and pharmaceutical
products containing the Licensed Compound (including without limitation Licensed
Products) for any and all uses.
(b) Upon termination of this Agreement by IntraBiotics for
BioSearch's material breach pursuant to Section 11.2, all licenses granted to
IntraBiotics shall survive, subject to the payment of a royalty to BioSearch
equal to [*] of Licensed Products by BioSearch, its Affiliates or
sublicensees, [*]. The provisions of Sections 8.4 through 8.8 shall apply
with respect to any such royalties payable under this Section 11.4(b). If
BioSearch is manufacturing Licensed Bulk Compound at the time of any
termination by IntraBiotics of this Agreement for BioSearch's material
breach, BioSearch shall continue to provide for manufacture of Bulk Licensed
Compound to the extent provided prior to notice of such termination until
such time as IntraBiotics is able to secure an equivalent alternative
commercial manufacturing source for the Territory, as requested by
IntraBiotics; PROVIDED, HOWEVER, that IntraBiotics shall pay to BioSearch its
Cost of Goods Sold for such Bulk Licensed Compound plus an additional [* ]
thereof. Further, upon IntraBiotics' request, BioSearch shall provide such
technical assistance as needed by IntraBiotics to commence manufacture of
Bulk Licensed Compound, at BioSearch's cost.
11.5 ACCRUED RIGHTS, SURVIVING OBLIGATIONS. Termination of this
Agreement shall not affect any accrued rights and remedies of either Party.
Additionally, the terms of Article 9 of this Agreement shall survive five (5)
years after termination or expiration of this Agreement and Sections 10.2
through 10.8, 11.4, 11.5 and Articles 7 (solely to the extent required to effect
the intent of Section 11.4, if applicable), 8 (solely to the extent required to
effect the intent of Section 11.4, if applicable), 12, 13 and 14 of this
Agreement shall survive any termination or expiration of this Agreement.
ARTICLE 12
REPRESENTATIONS AND WARRANTIES
12.1 MUTUAL REPRESENTATIONS AND WARRANTIES. Each Party hereby
represents and warrants:
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
24.
(a) CORPORATE POWER. Such Party is duly organized and validly
existing under the laws of the state or country of its incorporation and has
full corporate power and authority to enter into this Agreement and to carry out
the provisions hereof.
(b) DUE AUTHORIZATION. Such Party is duly authorized to
execute and deliver this Agreement and to perform its obligations hereunder.
(c) BINDING AGREEMENT. This Agreement is a legal and valid
obligation binding upon it and enforceable in accordance with its terms. The
execution, delivery and performance of this Agreement by such Party does not
conflict with any agreement, instrument or understanding, oral or written, to
which it is a Party or by which it may be bound, nor violate any law or
regulation of any court, governmental body or administrative or other agency
having jurisdiction over it. Such Party has not, and during the term of the
Agreement will not, grant any right to any Third Party with respect to its
Patents or Know-how that would conflict with the rights granted to the other
Party hereunder.
12.2 REPRESENTATIONS BY BIOSEARCH REGARDING MANUFACTURE OF BULK
LICENSED COMPOUNDS. BioSearch hereby warrants that the Bulk Licensed Compound
supplied hereunder will:
(a) comply with the specifications then in effect for Bulk
Licensed Compound;
(b) be manufactured, stored and shipped in compliance with all
applicable regional, federal, state and local laws and governmental regulations,
including without limitation the applicable current Good Manufacturing Practices
regulations;
(c) when shipped, will not be adulterated or misbranded within
the meaning of the Federal Food, Drug & Cosmetic Act and the regulations
promulgated thereunder; and
(d) be manufactured in accordance with all applicable laws and
governmental rules and regulations.
12.3 OTHER REPRESENTATIONS BY BIOSEARCH. BioSearch further represents
and warrants to IntraBiotics that:
(a) to the best of BioSearch's knowledge on the Effective
Date, there are no interferences or oppositions pending before any court or
administrative office or agency relating the BioSearch Patents;
(b) BioSearch has provided to IntraBiotics access to all
clinical records which describe all adverse event reports relating to Licensed
Products; and
(c) BioSearch owns all right, title and interest in and to the
Original IND, and BioSearch owns or controls all rights necessary to grant the
rights BioSearch purports to grant to IntraBiotics pursuant to this Agreement;
and
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
25.
(d) as of the Effective Date, BioSearch has not received any
notices of infringement or any written communications relating in any way to a
possible infringement with respect to the Licensed Compound or Licensed Products
in the Field, and is not aware that the practice of the BioSearch Patents and
BioSearch Know-how as contemplated by this Agreement will involve any
infringement or unauthorized use of any intellectual property rights of any
Third Party.
12.4 DISCLAIMER OF WARRANTIES. The Parties understand that the
activities to be undertaken pursuant to this Agreement will involve technologies
and products that have not been approved by any regulatory authority and that
neither Party guarantees the safety or usefulness of the Licensed Products.
EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY NATURE, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE.
ARTICLE 13
INDEMNIFICATION
13.1 INDEMNIFICATION BY BIOSEARCH. BioSearch hereby agrees to
indemnify, hold harmless and defend IntraBiotics against any and all expenses,
costs of defense (including without limitation attorneys' fees, witness fees,
damages, judgments, fines and amounts paid in settlement) and any amounts
IntraBiotics becomes legally obligated to pay because of any Third Party claim
or claims against it to the extent that such claim or claims result from (i)
BioSearch's negligence, (ii) BioSearch's breach or alleged breach of any
representation or warranty by BioSearch or of any other provision of this
Agreement, or (iii) the possession, manufacture, use, handling, storage, sale or
other disposition of Bulk Licensed Compound or of products containing the
Licensed Compound by BioSearch, its agents or licensees or sublicensees (other
than IntraBiotics), except to the extent such claim or claims arise from the
negligence, recklessness or willful misconduct of IntraBiotics or any breach of
any representation or warranty of IntraBiotics made pursuant to Section 12;
provided that IntraBiotics provides BioSearch with prompt notice of any such
claim and the exclusive ability to defend (with the reasonable cooperation of
IntraBiotics) and settle any such claim.
13.2 INDEMNIFICATION BY INTRABIOTICS. IntraBiotics hereby agrees to
indemnify, hold harmless and defend BioSearch against any and all expenses,
costs of defense (including without limitation attorneys' fees, witness fees,
damages, judgments, fines and amounts paid in settlement) and any amounts
BioSearch becomes legally obligated to pay because of any Third Party claim or
claims against it to the extent that such claim or claims arise out of (i)
IntraBiotics' negligence, recklessness or willful misconduct, (ii) IntraBiotics'
breach or alleged breach of any representation or warranty by IntraBiotics or of
any other provision of this Agreement, (iii) the possession, final manufacture,
use, sale or administration of Licensed Products by IntraBiotics or
IntraBiotics' Affiliates, licensees or sublicensees, except to the extent such
claim or claims arise from the negligence, recklessness or willful misconduct of
BioSearch
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
26.
or any breach of any representation or warranty of BioSearch made pursuant to
Section 12; provided that BioSearch provides IntraBiotics with prompt notice of
any such claim and the exclusive ability to defend (with the reasonable
cooperation of BioSearch) or settle any such claim, and provided further that
such indemnities shall not apply to losses resulting from BioSearch matters
covered under Section 13.1 above.
13.3 MECHANICS. In the event that the parties cannot agree as to the
application of Sections 13.1 and 13.2 above to any particular loss or claim, the
parties may conduct separate defenses of such claim. Each Party further reserves
the right to claim indemnity from the other in accordance with Sections 13.1 and
13.2 above upon resolution of the underlying claim, notwithstanding the
provisions of Sections 13.1 and 13.2 above requiring the indemnified Party to
tender to the indemnifying Party the exclusive ability to defend such claim or
suit.
ARTICLE 14
MISCELLANEOUS
14.1 ASSIGNMENT.
(a) Either Party may assign any of its rights or obligations
under this Agreement to any Affiliates; PROVIDED, HOWEVER, that such assignment
shall not relieve the assigning Party of its responsibilities for performance of
its obligations under this Agreement, and further provided that if a proposed
assignment would have an adverse financial impact upon the other Party (e.g., by
reason of changed tax treatment of payments due under this Agreement), such
assignment shall be subject to the other Party's prior written consent.
(b) This Agreement shall survive any such merger or
reorganization of either Party with or into, or such sale of assets to, another
party and no consent for such merger, reorganization or sale shall be required
hereunder; provided, that in the event of such merger, reorganization or sale,
no intellectual property rights of the acquiring corporation shall be included
in the technology licensed hereunder.
(c) This Agreement shall be binding upon and inure to the
benefit of the successors and permitted assigns of the Parties. Any assignment
not in accordance with this Agreement shall be void.
14.2 DISPUTE RESOLUTION.
(a) The Parties recognize that disputes as to certain matters
may from time to time arise during the term of this Agreement which relate to
either Party's rights and/or obligations hereunder or thereunder. It is the
objective of the Parties to establish procedures to facilitate the resolution of
disputes arising under this Agreement in an expedient manner by mutual
cooperation. To accomplish this objective, the Parties agree to follow the
procedures set forth in this Article 14 if and when a dispute arises under this
Agreement.
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
27.
Unless otherwise specifically recited in this Agreement, disputes among
the Parties will be resolved by reference first to their respective executive
officers designated below or their successors, for attempted resolution by good
faith negotiations within [*] after such notice is received. Said designated
officers are as follows:
For IntraBiotics: Chief Executive Officer
For BioSearch: President
In the event the designated executive officers are not able to resolve
such dispute, either Party may at anytime after the [*] period seek to resolve
the dispute through the means provided in Section 14.2(b).
(b) Any claim or controversy arising out of or
related to this Agreement or any breach hereof that is not resolved by the
designated officers as provided in this Agreement shall be resolved solely and
exclusively by final and binding arbitration held in New York, New York, U.S.A.
conducted by JAMS/Endispute, according to the then existing rules of
JAMS/Endispute. The arbitrator(s) selected shall have significant experience in
the biotechnology or pharmaceutical industry, and in conducting such proceeding
shall apply the substantive law of the State of New York as provided in Section
14.6, except that the interpretation of and enforcement of this Section shall be
governed by the Federal Arbitration Act. Any arbitration proceeding conducting
pursuant to this Section 14.2(b) shall take place in the city of New York, NY,
USA. Any award made by such arbitrator(s) shall be final and binding upon the
parties and a judgment of a court having jurisdiction may be entered on such
award. Notwithstanding the foregoing, disputes regarding the validity, scope or
enforceability of patents shall be submitted to a court of competent
jurisdiction in the country where such patent has issued.
14.3 FORCE MAJEURE. Neither Party shall lose any rights hereunder or be
liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, explosion, flood, strike, lockout, earthquake, embargo, act
of God, or any other similar cause beyond the control of the defaulting Party,
provided that the Party claiming force majeure has exerted all reasonable
efforts to avoid or remedy such force majeure.
14.4 COMPLIANCE WITH LAW. Each Party hereto shall comply with all
applicable laws, rules, ordinances, guidelines, consent decrees and regulations
of any applicable federal, state or other governmental authority.
14.5 EXPORT LAW COMPLIANCE. IntraBiotics understands and recognizes
that the Licensed Product and other materials made available to it hereunder may
be subject to the export administration regulations of the United States
Department of Commerce and other United States government regulations related to
the export of chemical compounds and medical devices.
14.6 GOVERNING LAW. This Agreement is deemed to have been entered into
in the State of Delaware, United States of America, as applied to contracts
entered into and performed
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
28.
entirely in Delaware by Delaware residents and its interpretation, construction,
and the remedies for its enforcement or breach are to be applied pursuant to and
in accordance with the laws of the State of Delaware.
14.7 ENTIRE AGREEMENT. This Agreement, including all Exhibits attached
hereto, and all documents delivered concurrently herewith, set forth all the
covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto and supersede and terminate all prior
agreements and understanding between the Parties. No subsequent alteration,
amendment, change or addition to this Agreement, shall be binding upon the
Parties hereto unless reduced to writing and signed by the respective authorized
officers of the Parties.
14.8 RELATIONSHIP OF THE PARTIES. Nothing hereunder shall be deemed to
authorize either Party to act for, represent or bind the other except as
expressly provided in this Agreement.
14.9 NOTICES. All notices hereunder shall be in writing and shall be
deemed given if delivered personally or by facsimile transmission (receipt
verified), telexed, mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, to the Parties
at the following addresses (or at such other address for a Party as shall be
specified by like notice; provided, that notices of a change of address shall be
effective only upon receipt thereof).
If to BioSearch,
addressed to: BIOSEARCH ITALIA S.P.A.
Xxx Xxxxxxx, 00
00000 Xxxxxxxxx, Xxxxx
Attention: President
Telephone: 00.0.00000.000
Telecopy: 39.2.96474.400
If to IntraBiotics,
addressed to: INTRABIOTICS PHARMACEUTICALS INC.
0000 Xxxxx Xxxxx Xxxxxx
Xxxxxxxx Xxxx, XX 00000
Attention: Chief Executive Officer
Telephone: (000) 000-0000
Telecopy: (000) 000-0000
With copy to: XXXXXX GODWARD LLP
Five Palo Alto Square
0000 Xx Xxxxxx Xxxx
Xxxx Xxxx, XX 00000-0000
Attention: Xxxxxx X. Xxxxx, Esq.
Telephone: (000) 000-0000
Telecopy: (000) 000-0000
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
29.
14.10 WAIVER. Except as specifically provided for herein, the waiver
from time to time by either of the Parties of any of their rights or their
failure to exercise any remedy shall not operate or be construed as a continuing
waiver of same or of any other of such Party's rights or remedies provided in
this Agreement.
14.11 SEVERABILITY. If any term, covenant or condition of this
Agreement or the application thereof to any Party or circumstance shall, to any
extent, be held to be invalid or unenforceable, then (i) the remainder of this
Agreement, or the application of such term, covenant or condition to Parties or
circumstances other than those as to which it is held invalid or unenforceable,
shall not be affected thereby and each term, covenant or condition of this
Agreement shall be valid and be enforced to the fullest extent permitted by law;
and (ii) the Parties hereto covenant and agree to renegotiate any such term,
covenant or application thereof in good faith in order to provide a reasonably
acceptable alternative to the term, covenant or condition of this Agreement or
the application thereof that is invalid or unenforceable, it being the intent of
the Parties that the basic purposes of this Agreement are to be effectuated.
14.12 OFFICIAL LANGUAGE. The official text of this Agreement and any
appendices, exhibits and schedules hereto, or any notice given or accounts or
statements required by this Agreement shall be in English. In the event of any
dispute concerning the construction or meaning of this Agreement, reference
shall be made only to this Agreement as written in English and not to any other
translation into any other language.
14.13 HEADINGS. The Section and paragraph headings contained herein are
for the purposes of convenience only and are not intended to define or limit the
contents of said sections or paragraphs.
14.14 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the Parties have executed this Agreement in
duplicate originals by their proper officers as of the Effective Date.
INTRABIOTICS PHARMACEUTICALS, INC. BIOSEARCH ITALIA, S.P.A.
By: /s/ Xxxxxxx X. Xxxxxx By:/s/ Francesco Parenti
------------------------------- -------------------------------
Title: President and CEO Title: President
---------------------------- ----------------------------
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
30.
EXHIBIT 7.4
BULK LICENSED COMPOUND SPECIFICATIONS
TEST SPECIFICATION TEST METHOD
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ]
[ * ] [ * ]
[ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] [ * ] [ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
i.
